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single-blind randomized controlled trials for this condition.
In 2010 and 2013, two impactful studies with high levels of evidence were reported by Coombes et al. 7, 8 In 2010, they performed a well-designed meta-analysis and concluded that corticosteroid injection for lateral epicondylitis achieved favorable short-term results. However, at 6 months and 1 year, pain had returned. In fact, patients who received corticosteroid injections reported worse pain than patients who received other interventions, such as nonsteroidal antiinflammatory drugs, physical therapy, platelet-rich plasma injection, or no treatment. Although the studies included in the analysis did not address methodologic features such as concealed allocation, intention-to-treat, and treatment masking, the investigators concluded that corticosteroid injections actually worsen symptoms of lateral epicondylitis in the long term. In 2013, the same team reported the results of an elaborate double-blind randomized controlled trial comparing corticosteroid and placebo injections. They addressed the methodologic deficiencies of previous studies and reached the same conclusion: although symptoms initially improved following corticosteroid injections, symptoms actually worsened by the 6-month mark. Researchers theorized that corticosteroid injection could aggravate the healing process of the injured tendon. 9 Or, more simply, the immediate pain relief afforded by corticosteroid injection could encourage patients to return to aggravating activities sooner than they may have following other treatments. This may cause further damage to tendons, rather than promote healing. 10, 11 Since the publication of their studies, several other groups have reported on randomized controlled trials comparing corticosteroid injection to other treatments; none of these conclude that corticosteroid injections possess any long-term benefit. [12] [13] [14] [15] [16] Based on the standard levels of evidence for therapeutic studies established by the Oxford Centre for Evidence-Based Medicine, 17 the aforementioned meta-analysis and randomized controlled trial are classified as a Level I and a Level II study, respectively. Grading recommendations from the American Society of Plastic Surgeons place a strong recommendation on "Evidence from two or more 'High' quality studies with consistent findings for recommending for or against the intervention." 18 Thus, the combination of these two studies provides strong evidence against the routine injection of steroid medications to treat lateral epicondylitis, not only because they were published in high-impact journals, but also because of their quality research design.
It remains unknown whether the publication of these studies has had an appreciable impact on daily clinical practice. Following the basic principles of evidence-based medicine, clinical practice patterns should reflect recommendations from high-level research evidence within an appropriate amount of time to remain clinically relevant. Nevertheless, several authors have reported on the difficulty of changing clinical practice, even in the face of overwhelming evidence. For example, following the publication of two landmark studies, both of which demonstrated that percutaneous coronary intervention does not improve outcomes for patients with stable coronary artery disease, Siontis et al. reported that more than 15 percent of articles citing those studies concluded that percutaneous coronary intervention was, indeed, efficacious. 19 In previous epidemiologic studies performed by our group, it was discovered that approximately 90 percent of patients with thumb basilar joint arthritis were treated with trapeziectomy with soft-tissue arthroplasty despite accumulating high-level evidence suggesting that this procedures does not lead to superior outcomes and may be less cost-effective than other surgical options. 20, 21 Undoubtedly, evidence-based medicine has contributed to medical advances, but it is still unknown how and from where high-level evidence spreads to result in changes in clinical practice. The specific aim of this study was to clarify the spread of evidence, as reflected by changes in clinical activity, and to identify factors that hinder or enhance evidence diffusion.
MATERIALS AND METHODS
This retrospective claims analysis adheres fully to the guidelines for observational studies listed in the Strengthening the Reporting of Observational Studies in Epidemiology statement. 22 This study was exempt from institutional review board oversight.
Data Source
We performed a retrospective analysis using the Truven MarketScan Commercial Claims and Encounters and Medicare Supplement and Coordination of Benefits database from 2009 to 2015. The MarketScan database contains deidentified health insurance claims for inpatient care, outpatient care, and prescription drugs. The data are collected from more than 50 million people covered by health care plans administered in the United States by large employers and from managed care organizations, Medicare Part C, and multistate Medicaid, creating a large enough sample to be representative of Americans covered by commercial insurance or Medicaid. 23 All data regarding diagnosis, treatment, and cost are reported at the time of service.
Creation of Analysis Cohort
Inclusion and exclusion criteria are listed in Table 1 . This study included claims citing a diagnosis of lateral epicondylitis and at least one of the following treatments: corticosteroid injection, platelet-rich plasma injection, physical therapy, or surgery. We identified diagnoses using We excluded claims from patients who had any diagnosis of tendinopathy or enthesopathy other than lateral epicondylitis during the study period because the Current Procedural Terminology code for corticosteroid injection does not specify the body region. Thus, we avoided including patients who were diagnosed with lateral epicondylitis but received corticosteroid injection treatment for a different condition (e.g., Achilles tendinopathy). We used the insurance type variable recorded in MarketScan to categorize insurance plan type as either fee-for-service or capitated managed care. We categorized provider specialty into two groups: plastic or orthopedic surgeons, and all other physicians.
Data Analysis
We used descriptive statistics to summarize the characteristics of the cohort, including sex, age, region, type of insurance, and provider specialty by calendar year. The use rate for each treatment was defined as the total number of claims citing that particular procedure for any given year divided by the total number of claims for that same year. To detect any change in the use of corticosteroid injection after the publication of articles with a high level of evidence, we compared the annual rate before and after publication. We calculated odds ratios to identify factors that may influence which procedures particular patients received. Because patients may receive more than one treatment during the study period, we used multivariable logistic regression with a generalized estimating equation model to calculate estimated odds ratio and 95 percent confidence intervals to address the potential problem of correlated data. The correlation structure was based on an autoregressive model, which is usually used for time-series data analysis. We adjusted all analyses for sex, age, region, type of insurance, provider specialty, and calendar year. All tests were performed using a two-sided significance level of p = 0.05.
The procedures used to treat lateral epicondylitis are applied at differing frequencies. For instance, a patient may undergo physical therapy several times per week over a period of months. In contrast, corticosteroid or platelet-rich plasma injections are given only once in a 2-month period or even less frequently. Therefore, if we simply compared the actual number of claims in our specified period, the rate of physical therapy use may be magnified. To protect against this, we performed a sensitivity test that only counted whether a patient received a treatment in a month, rather than the number of times a treatment was received. In other words, for each patient in the data set and for each month in the study period, the four treatments (corticosteroid or platelet-rich plasma 
RESULTS
Our primary analysis included a total of 711,726 claims from 156,547 patients (Fig. 1) . The baseline characteristics of the research cohort are listed in Table 2 . Our study included approximately 100,000 encounters per year, and approximately 56 percent of total encounters were with female patients. Similar to previous epidemiologic studies, the 40-to 54-year age group showed the highest number of claims. 1, 2, 24 Approximately 90 percent of patients used feefor-service insurance.
After publication of the two impactful articles in November of 2010 and February of 2013, the corticosteroid injection rate did not decrease. In fact, we found that the corticosteroid injection rate actually increased over time ( Fig. 2 and Table 3 ). Patients older than 55 years were less likely to undergo surgical treatment than younger patients (OR, 0.65; 95 percent CI, 0.60 to 0.71). Procedure received was significantly related to geographic region (Table 3) . For example, patients in the South were significantly more likely to receive corticosteroid injection. Patients in the Northeast and West were more likely to receive physical therapy. Likewise, those same patients were less likely to undergo surgery. As expected, patients who were treated by plastic or orthopedic surgeons were significantly more likely to undergo surgery (OR, 6.19; 95 percent CI, 5.77 to 6.65), corticosteroid injection (OR, 2.48; 95 percent CI, 2.43 to 2.52), and plateletrich plasma injection (OR, 3.26; 95 percent CI, 2.41 to 4.41), whereas patients treated by other physicians were far more likely to receive physical therapy. The effect of high-level evidence on corticosteroid injection rate did not differ based on provider specialty. The rate of corticosteroid injection increased among plastic and orthopedic surgeons and among physicians from other specialties or primary care physicians (Table 4) . *The meta-analysis of randomized controlled studies was published on November 20, 2010, whereas the well-designed randomized controlled trial was published on February 6, 2013.
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to physicians in primary care or another specialty. We suspect this variation is a result of the novelty of this method of treatment being used for lateral epicondylitis.
As demonstrated in the multivariable analysis, the evidence-based publications did not alter the treatment received in a meaningful way within the study period. The odds of a patient receiving a corticosteroid injection actually increased slightly over time, whereas there was no significant change in the odds of undergoing therapy or surgery. The results of our sensitivity analyses indicated that the variation in frequency of use between any combinations of possible treatments did not introduce bias or change the conclusions of our study. Likewise, the large proportion of missing data in physician specialty and region did not affect our conclusions.
DISCUSSION
High-level evidence may not be sufficient to influence existing clinical practice patterns. In this study, we found that even after publication of two high-quality articles dissuading physicians from using corticosteroid injection, the odds of a patient receiving this treatment for lateral epicondylitis did not decrease. The impactful evidence did not alter the treatment received in any way. In contrast, several patient-related factors, such as sex, age, and type of insurance, continue to affect the treatment received. Moreover, there continues to be significant regional differences in treatment.
Previous research indicates that only 14 percent of all new discoveries ultimately become a persistent part of daily clinical practice. 25 To date, several authors have reported on barriers that prevent evidence diffusion. Cabana et al. performed a systematic review and reported seven adherence barriers: lack of awareness, lack of familiarity, lack of agreement, lack of self-efficacy, lack of outcome expectancy, adherence to previous practice, and external barriers. 26 Hay et al. identified physicians' tendency to rely on clinical experience, the opinions of colleagues, and evidence summarized in electronic clinical resources (e.g., WebMD, ClinicalKey, or Mayo Clinic) rather than on original articles. 27 Difficulty in searching for evidence or preparing resources for implementation may also CS, corticosteroid; PRP, platelet-rich plasma. *The meta-analysis of randomized controlled studies was published on November 20, 2010, whereas the well-designed randomized controlled trial was published on February 6, 2013. †p < 0.05. discourage providers from adopting evidencebased clinical practice. 28 In our study, we found numerous patient-level factors to be associated with the type of treatment received. Geographic region was shown to strongly influence the odds of receiving a particular treatment, supporting the existence of regional variations in surgical decision-making. Regional variations occur frequently and may be explained by some of the same adherence barriers preventing the spread of novel evidence, such as lack of familiarity, lack of outcome expectancy, and adherence to previous practice. We further speculate that the regional discrepancies for lateral epicondylitis treatment are an extension of variations that present themselves on the provider level, such as physician background or resources available. These factors may also contribute to the persistence of conventional practice patterns despite contradictory evidence.
We also found that the use rate for corticosteroid injection decreased among neither plastic/ orthopedic surgeons nor other physicians based on the introduction of new evidence. Patients treated by orthopedic or plastic surgeons were significantly more likely to receive corticosteroid injection for lateral epicondylitis than were patients treated by other physicians. Orthopedic or plastic surgeons may be hesitant to abandon corticosteroid injections as a treatment option because of the relatively low cost or the dearth of evidence supporting a single superior treatment. It is also possible that surgeons were aware of the evidence, but patients still chose to receive corticosteroid injections for the short-term reduction in symptoms. Harmful long-term results may not be easily understood by patients who seek immediate relief. Facing an ethical dilemma between addressing patients' immediate needs and providing the best care, we must continue to guide patients to choose an appropriate treatment while balancing the fine line between respecting the wishes of the patient and ensuring nonmaleficence. Because lateral epicondylitis is a common disease, family doctors and general surgeons may be consulted for treatment. In our cohort, approximately 30 percent of patients were treated by "other physicians." Patients who were treated by these physicians predominantly received physical therapy, yet some received surgery or corticosteroid injections. There may be additional barriers such as a lack of awareness or the familiarity of previous practices that hinder these physicians from altering practice based on new evidence. The latest evidence recommends physical therapy or other Plastic and Reconstructive Surgery • May 2018 conservative treatments such as analgesic or antiinflammatory medication, rest, and ice in place of corticosteroid injection. 7 Insurance type also affected the treatment received. Most notably, patients with managed care insurance were significantly more likely to receive surgery than patients with the other types of insurance. Considering that surgery is typically more expensive, this finding may reflect that patients with a managed care plan show less concern about treatment costs. In contrast, patients with fee-for-service insurance were more likely to undergo physical therapy, a less costly treatment than surgery.
This study had several limitations. First, this project, like all studies based on large administrative data sets, is dependent on the accuracy of coding and diagnosis for the conditions of interest. This factor is especially relevant to this study because there is no definitive test for lateral epicondylitis. To protect against miscoding, we included only insurance claims with both a diagnosis for lateral epicondylitis and an appropriate treatment code. In addition, we excluded any patients who had a diagnosis of tendinopathy or enthesopathy in any other part of the body during the study period. We were unable to distinguish cases of bilateral disease or misdiagnosis because of the lack of clinical details available, which may have artificially inflated treatment rates. However, these factors were less of a concern because our outcome of interest was treatment choice when a patient had been diagnosed with lateral epicondylitis. Our results then were based less on the accurate diagnosis of lateral epicondylitis than on the accurate identification of treatment received for lateral epicondylitis.
Second, the two impactful articles were published relatively recently; our analysis included a follow-up period of only 5 years 2 months after the meta-analysis publication and 2 years 10 months after the publication of the randomized controlled trial results. Popular wisdom says that it takes approximately 17 years for novel findings in any field of health research to be introduced into daily clinical practice. 25, 29, 30 However, as Morris and colleagues 29 describe in their review, the methodologies that previous investigations use to calculate time lags are not consistent. For example, one study defined the time lag as the time frame between publication of a clinical trial and the publication of a clinical guideline, 31 whereas others measured the time between an initial publication and a highly cited publication. 32, 33 Despite the length of our follow-up period, our findings emphasize the need for improvements in the translation of research findings to practice. Finally, we were unable to assess whether the physicians who continued to provide corticosteroid injections had actually read the two high-quality studies that we reference. It is entirely possible that we did not observe any substantial changes in the rates of injection because providers were oblivious to the newfound evidence. However, this scenario also underscores the need for more effective methods to distribute and disseminate research findings into practice.
Despite these limitations, this project has demonstrated that inducing evidence-based change to clinical practice requires more than simply publishing evidence. To promote change, researchers should build a strategy to disseminate and implement findings as part of their project plans. 34 As it currently stands, dissemination and implementation are afterthoughts, considered only once the project has been completed. Researchers must understand the role of their findings in modern clinical practice before initiating a study. In addition, major associations and high-level education institutions, which typically hold more power and influence than the individual researcher, should also be responsible for promoting the dissemination and implementation of the latest evidence. The Clinical and Translational Science Award program from the National Institutes of Health, for instance, is one example of a program implemented to facilitate a network not only between basic and clinical research but also from clinical research into practice. Similar efforts that promote methods for new findings to reach their intended populations should be mirrored across organizations. The findings of our analysis highlight the need for further efforts focusing on the direct translation of evidence into practice. 
